Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

James Larkin, MD, PhD
Published: Tuesday, Sep 15, 2015



James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus, single-agent lenvatinib, and single-agent everolimus in patients with renal cell carcinoma (RCC).

The three-arm study looked at patients who previously received sunitinib or pazopanib, Larkin explains. In patients who received everolimus, PFS was approximately 5 months, while PFS was 7 months in patients who received lenvatinib. Patients who received the combination had a median PFS of 14 months.

Toxicities associated with the combination, which included high blood pressure and diarrhea, were manageable and expected.



James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus, single-agent lenvatinib, and single-agent everolimus in patients with renal cell carcinoma (RCC).

The three-arm study looked at patients who previously received sunitinib or pazopanib, Larkin explains. In patients who received everolimus, PFS was approximately 5 months, while PFS was 7 months in patients who received lenvatinib. Patients who received the combination had a median PFS of 14 months.

Toxicities associated with the combination, which included high blood pressure and diarrhea, were manageable and expected.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x